{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=5", "query": { "intervention": "liposomal doxorubicin", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1374, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T18:52:18.955Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00390793", "title": "Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "BCR-ABL1 Fusion Protein Expression", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Philadelphia Chromosome Positive", "Recurrent Acute Lymphoblastic Leukemia", "t(9;22)" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2006-09-28", "completion_date": "2024-02-02", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-10-13T18:52:18.955Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00390793" }, { "nct_id": "NCT00740805", "title": "Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Solid Neoplasm" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2008-08-18", "completion_date": "2026-10-22", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-13T18:52:18.955Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00740805" }, { "nct_id": "NCT02700022", "title": "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "Follicular Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-10", "completion_date": "2017-08-18", "has_results": false, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-10-13T18:52:18.955Z", "location_count": 2, "location_summary": "Duarte, California • Chapel Hills, North Carolina", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chapel Hills", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02700022" }, { "nct_id": "NCT00003296", "title": "Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Liver Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "1998-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-10-13T18:52:18.955Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Providence, Rhode Island", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003296" }, { "nct_id": "NCT00116961", "title": "Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Velcade", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2005-06", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-02-07", "last_synced_at": "2026-10-13T18:52:18.955Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00116961" }, { "nct_id": "NCT00304070", "title": "Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage I Adrenal Cortical Carcinoma AJCC v7", "Stage II Adrenal Cortical Carcinoma AJCC v7", "Stage III Adrenal Cortical Carcinoma AJCC v7", "Stage IV Adrenal Cortical Carcinoma AJCC v7" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Mitotane", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 78, "start_date": "2007-05-03", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-10-13T18:52:18.955Z", "location_count": 81, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 70 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00304070" }, { "nct_id": "NCT02213913", "title": "Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "B-cell Chronic Lymphocytic Leukemia", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Progressive Hairy Cell Leukemia, Initial Treatment", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage 0 Chronic Lymphocytic Leukemia", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Adult Hodgkin Lymphoma", "Stage I Adult Immunoblastic Large Cell Lymphoma", "Stage I Chronic Lymphocytic Leukemia", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Small Lymphocytic Lymphoma", "Stage II Adult Hodgkin Lymphoma", "Stage II Chronic Lymphocytic Leukemia", "Stage II Small Lymphocytic Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma", "Testicular Lymphoma", "Untreated Hairy Cell Leukemia", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "quality-of-life assessment", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2014-07-29", "completion_date": "2024-10-29", "has_results": true, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-13T18:52:18.955Z", "location_count": 6, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213913" }, { "nct_id": "NCT02412670", "title": "Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Upper Tract Urothelial Carcinoma" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Nephroureterectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2015-08-27", "completion_date": "2022-05-10", "has_results": true, "last_update_posted_date": "2023-07-10", "last_synced_at": "2026-10-13T18:52:18.955Z", "location_count": 134, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Colorado Springs, Colorado + 93 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02412670" }, { "nct_id": "NCT04623541", "title": "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Richter's Syndrome", "Treatment-naïve High Risk Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pirtobrutinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2020-11-25", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-13T18:52:18.955Z", "location_count": 23, "location_summary": "Birmingham, Alabama • California City, California • Duarte, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "California City", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04623541" }, { "nct_id": "NCT00546156", "title": "Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ian E. Krop, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2007-10", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2021-05-18", "last_synced_at": "2026-10-13T18:52:18.955Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Hooksett, New Hampshire", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hooksett", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00546156" } ] }